Phathom Pharmaceuticals, Inc. (PHAT)

NASDAQ: PHAT · Real-Time Price · USD
2.290
-0.110 (-4.58%)
At close: May 8, 2025, 4:00 PM
2.330
+0.040 (1.75%)
After-hours: May 8, 2025, 7:18 PM EDT
-4.58%
Market Cap 159.49M
Revenue (ttm) 81.86M
Net Income (ttm) -345.79M
Shares Out 69.65M
EPS (ttm) -5.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,912,068
Open 2.400
Previous Close 2.400
Day's Range 2.220 - 2.400
52-Week Range 2.210 - 19.710
Beta 0.15
Analysts Strong Buy
Price Target 17.80 (+677.29%)
Earnings Date May 1, 2025

About PHAT

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinoph... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2019
Employees 427
Stock Exchange NASDAQ
Ticker Symbol PHAT
Full Company Profile

Financial Performance

In 2024, Phathom Pharmaceuticals's revenue was $55.25 million, an increase of 8001.47% compared to the previous year's $682,000. Losses were -$334.33 million, 65.8% more than in 2023.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for PHAT stock is "Strong Buy." The 12-month stock price forecast is $17.8, which is an increase of 677.29% from the latest price.

Price Target
$17.8
(677.29% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointe...

7 days ago - GlobeNewsWire

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript

7 days ago - Seeking Alpha

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providers Net revenues of $28.5 million reported for Q1 Filled VOQUEZNA prescr...

Other symbols: ITCI
7 days ago - GlobeNewsWire

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

FLORHAM PARK, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin...

10 days ago - GlobeNewsWire

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

• Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical c...

15 days ago - GlobeNewsWire

Frazier Life Sciences Appoints Aditya Kohli to Partner

PALO ALTO, Calif.--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. ...

Other symbols: HLVX
21 days ago - Business Wire

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin...

Other symbols: CDTX
22 days ago - GlobeNewsWire

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin...

5 weeks ago - GlobeNewsWire

Phathom Pharmaceuticals Announces Leadership Succession

FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin...

5 weeks ago - GlobeNewsWire

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

For the first time, Thompson shares his journey living with gastroesophageal reflux disease (GERD) and experience using VOQUEZNA, as part of the new GERD IS NO JOKE campaign VOQUEZNA is a potassium co...

5 weeks ago - GlobeNewsWire

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Eric Sciorilli - Head, Investor Relations Terrie Curran - President & Chief ...

2 months ago - Seeking Alpha

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

FLORHAM PARK, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin...

2 months ago - GlobeNewsWire

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

2 months ago - GlobeNewsWire

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

3 months ago - GlobeNewsWire

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

5 months ago - GlobeNewsWire

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President & C...

6 months ago - Seeking Alpha

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

6 months ago - GlobeNewsWire

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

6 months ago - GlobeNewsWire

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

6 months ago - GlobeNewsWire

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

FLORHAM PARK, N.J., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

9 months ago - GlobeNewsWire

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President and CE...

9 months ago - Seeking Alpha

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

9 months ago - GlobeNewsWire

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease (GERD) VOQUEZNA met its primary endpoint in its Phase 3 pivotal trial by demonstrating a signifi...

10 months ago - GlobeNewsWire

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

Phathom Pharmaceuticals stock has significantly declined since 2021, despite securing FDA approval for Vonoprazan to treat H. pylori infection and GERD. The company faced delays in launching its produ...

11 months ago - Seeking Alpha

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Results Conference Call May 9, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President & Chief E...

1 year ago - Seeking Alpha